[Clinical effectiveness of prospidin in systemic lupus erythematosus (results of a 6-month follow-up)].

Abstract

The efficacy of the new Soviet antirheumatoid drug prospidin (the long-term treatment dose 1.4-6.0 g) was studied in 22 patients with significant lupus erythematosus (SLE). As a result of prospidin therapy administered for a month, 3 patients considerably improved and 19 patients improved. For 6 months the maintenance therapy was given to 15 patients. Considerable improvement was recorded in 4 and improvement in 9 patients. No effect was marked in one patient and one female patient died. The drug was tolerated well. No side effects requiring prospidin withdrawal were recorded. Prospidin exerted the most powerful effect with respect to lupoid nephritis, the articulation syndrome, and cytopenias. In accordance with the clinical improvement, the drug was established to return the immunological shifts common to SLE to normal. The drug may be viewed as a new basic agent for the treatment of SLE.

• Authors: E V Benenson, E M Mirrakhimova
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 61 Issue 5 Pg. 21-6 ( 1989) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Klinicheskaia éffektivnost' prospidina pri sistemnoĭ krasnoĭ volchanke (rezul'taty 6-mesiachnogo nabliudeniia).
• PMID: 2781483 (Publication Type: English Abstract, Journal Article)

Chemical References

• Piperazines
• Prospidium

Topics

• Follow-Up Studies
• Humans
• Lupus Erythematosus, Systemic (blood, drug therapy)
• Piperazines (therapeutic use)
• Prospidium (therapeutic use)